studies

1004A AASLD ABSTRACTS HEPATOLOGY, October, 2015
reported to regulate HCV virion secretion through interaction
with phosphatidylinositol 4-phosphate. We confirmed that
GOLPH3 knockdown reduced HCV virion secretion in JFH1 cell
culture supernatants and HBV DNA and pregenomic RNA levels
in HepG2.2.15 cells. Moreover, we found that GORASP2
knockdown increased both intracellular HCV RNA replication
and virion trafficking and release to the supernatant. Conclusions:
We conclude that GORASP2 protein regulates HCV and
HBV replication through RNA replication and virion trafficking.
Further exploration of the mechanism by which GORASP2 or
GOLPH3 alters viral nucleic acid replication and virion trafficking
are warranted.
Disclosures:
Dahlene Fusco - Grant/Research Support: Gilead
Raymond T. Chung - Grant/Research Support: Gilead, Mass Biologics, Abbvie,
Merck, BMS
The following authors have nothing to disclose: Dachuan Cai, Jian Hong, Xiao
Liu, Sae Hwan Lee, Esperance A. Schaefer, Cynthia Brisac, Anna Lidofsky,
Wenyu Lin
compared to those without sustained HBeAg seroconversion
were shown in table. Multivariate analysis found pre-treatment
HBVDNA < 7 logIU/ml (OR=5.7, 95%CI=1.1-28.6, p=0.03)
and rs12794714 CYP2R1 TT genotype (OR=4.1, 95%CI=1.1-
15.5, p=0.04) strongly predicted HBeAg seroconversion at 24
weeks post treatment. HBVDNA before treatment and at week
12 was significant lower in rs12794714 CYP2R1 TT genotype
than non-TT genotype. There was no association between
the remaining 12 SNPs and treatment response, including sustained
HBeAg seroconversion, combined response (HBeAg
loss and HBVDNA